DK0914146T3 - Morfogenbehandling af kronisk nyresvigt - Google Patents

Morfogenbehandling af kronisk nyresvigt

Info

Publication number
DK0914146T3
DK0914146T3 DK97922726T DK97922726T DK0914146T3 DK 0914146 T3 DK0914146 T3 DK 0914146T3 DK 97922726 T DK97922726 T DK 97922726T DK 97922726 T DK97922726 T DK 97922726T DK 0914146 T3 DK0914146 T3 DK 0914146T3
Authority
DK
Denmark
Prior art keywords
renal failure
chronic renal
treatment
morphogen treatment
risk
Prior art date
Application number
DK97922726T
Other languages
Danish (da)
English (en)
Inventor
Kuber T Sampath
Charles M Cohen
Slobodan Vukicevic
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of DK0914146T3 publication Critical patent/DK0914146T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK97922726T 1996-05-06 1997-05-06 Morfogenbehandling af kronisk nyresvigt DK0914146T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/643,321 US6498142B1 (en) 1996-05-06 1996-05-06 Morphogen treatment for chronic renal failure
EP97922726A EP0914146B1 (en) 1996-05-06 1997-05-06 Morphogen treatment for chronic renal failure

Publications (1)

Publication Number Publication Date
DK0914146T3 true DK0914146T3 (da) 2005-01-31

Family

ID=24580305

Family Applications (2)

Application Number Title Priority Date Filing Date
DK97922726T DK0914146T3 (da) 1996-05-06 1997-05-06 Morfogenbehandling af kronisk nyresvigt
DK97923567T DK0910400T3 (da) 1996-05-06 1997-05-06 Terapier for kronisk nyresvigt

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97923567T DK0910400T3 (da) 1996-05-06 1997-05-06 Terapier for kronisk nyresvigt

Country Status (11)

Country Link
US (5) US6498142B1 (es)
EP (2) EP0914146B1 (es)
JP (4) JP2000510835A (es)
AT (2) ATE245997T1 (es)
AU (2) AU2933997A (es)
CA (2) CA2254953C (es)
DE (2) DE69730966T2 (es)
DK (2) DK0914146T3 (es)
ES (2) ES2230604T3 (es)
PT (2) PT910400E (es)
WO (2) WO1997041881A1 (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
CA2104678C (en) * 1991-03-11 2002-05-14 Charles M. Cohen Protein-induced morphogenesis
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
ATE278414T1 (de) 1997-05-05 2004-10-15 Curis Inc Therapien zur behandlung von akutem nierenversagen
WO1998050061A1 (en) * 1997-05-07 1998-11-12 Biogen, Inc. Novel therapies for cystic kidney disease
DE69714035T2 (de) 1997-08-14 2003-03-06 Sulzer Innotec Ag Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren
US6203788B1 (en) * 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
AU1706499A (en) * 1997-12-04 1999-06-16 Curis, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
JP2002526034A (ja) * 1998-07-28 2002-08-20 ザ ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン 増殖分化因子−１１
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US6992066B2 (en) 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
DK1214091T3 (da) * 1999-09-14 2006-08-28 Biogen Idec Inc Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister
US20020173453A1 (en) * 2000-12-15 2002-11-21 Rama Akella Method of treating renal injury
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7232802B2 (en) * 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
AU2003268219B2 (en) * 2002-08-28 2009-09-24 Barnes-Jewish Hospital Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
WO2005037232A2 (en) 2003-10-17 2005-04-28 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US7844367B2 (en) 2003-12-23 2010-11-30 Rain Bird Corporation Code replacement for irrigation controllers
EP1732524B1 (en) 2004-03-30 2012-08-22 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
JP2008500816A (ja) * 2004-03-31 2008-01-17 ゼンコー・インコーポレイテッド 改善された性質を有するｂｍｐ−７変異体
US20100150885A1 (en) 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US7771995B2 (en) * 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
JP2009515529A (ja) * 2005-11-14 2009-04-16 メリアル リミテッド 腎不全のための遺伝子療法
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
US20070196810A1 (en) 2006-01-24 2007-08-23 Northfield Laboratories Inc. Polymerized Hemoglobin Media and its Use in Isolation and Transplantation of Islet Cells
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
PL2035835T3 (pl) * 2006-05-30 2012-05-31 Antibodyshop As Sposoby szybkiej oceny ciężkości urazu
US7722665B2 (en) * 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
EP2047862B9 (en) * 2006-07-21 2013-04-10 Chugai Seiyaku Kabushiki Kaisha Remedy for renal disease
US20080255181A1 (en) * 2006-12-15 2008-10-16 University Of Heidelberg Methods for treating podocyte-related disorders
EP2148706A2 (en) * 2007-04-24 2010-02-03 Advanced Technologies and Regenerative Medicine, LLC Engineered renal tissue
DE102007034580B4 (de) * 2007-07-13 2012-11-08 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Biomaterial basierend auf einem hydrophilen polymeren Träger
US20090155245A1 (en) * 2007-12-18 2009-06-18 Fang Carrie H Treatment for Organ Regeneration with Combination of Drug and Biologics
JP2011523357A (ja) * 2008-05-06 2011-08-11 ジョスリン ダイアビーティス センター インコーポレイテッド 褐色脂肪細胞分化を誘導するための方法および組成物
JP5485885B2 (ja) * 2008-06-24 2014-05-07 株式会社根本杏林堂 薬液注入装置、この薬液注入装置を有する透視撮像システム、薬液注入装置のコンピュータプログラムおよびデータ処理方法
CN102187220B (zh) * 2008-08-28 2015-08-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CA2735590A1 (en) * 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2012506538A (ja) * 2008-10-21 2012-03-15 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
NZ607703A (en) 2008-10-21 2014-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102264230B (zh) 2008-11-10 2014-12-10 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CA2743253A1 (en) * 2008-11-22 2010-05-27 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2393937A4 (en) * 2009-02-06 2012-08-08 Astute Medical Inc METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
US20100204124A1 (en) * 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members
WO2010093925A2 (en) * 2009-02-12 2010-08-19 Stryker Corporation PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE
EP2406281B1 (en) * 2009-03-12 2016-02-17 Haase Investments UG Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells
BR112012002711A2 (pt) 2009-08-07 2016-11-01 Astute Medical Inc metodo para avaliar o estado renal em um individuo, e, medicao de proteina
JP2013518808A (ja) 2009-09-17 2013-05-23 ストライカー コーポレイション 骨形成タンパク質のｐＨを制御するための緩衝液
CN102725635B (zh) 2009-11-07 2015-05-20 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
MX342967B (es) 2009-12-20 2016-10-19 Astute Medical Inc Metodos y composiciones para la diagnosis y prognosis de lesion renal y falla renal.
EP2516456A1 (en) 2009-12-22 2012-10-31 Stryker Corporation Bmp-7 variants with reduced immunogenicity
MX341191B (es) 2010-02-05 2016-08-10 Astute Medical Inc Metodos y composiciones para diagnostico y prognosis de lesion renal y falla renal.
JP5998057B2 (ja) 2010-02-26 2016-11-30 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断と予後のための方法と組成物
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
NZ605561A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3339860A1 (en) 2010-06-23 2018-06-27 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5985480B2 (ja) 2010-08-20 2016-09-06 ワイス・エルエルシー デザイナー骨形成タンパク質
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
KR20150088243A (ko) 2012-10-08 2015-07-31 리립사, 인크. 고혈압 및 고칼륨혈증을 치료하기 위한 칼륨-결합제
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
CN107976547B (zh) 2013-01-17 2020-08-25 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
WO2015069998A1 (en) * 2013-11-11 2015-05-14 General Electric Company Method for reducing error in rotor speed measurements
EP2944326B1 (en) 2014-05-16 2018-11-21 Cyanagen Srl Tricarbocyanine-cyclodextrin-conjugates and their use for the diagnosis of kidney diseases
EP3256585A4 (en) 2015-02-13 2018-08-15 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
AU2017277305A1 (en) 2016-06-06 2018-12-20 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
JP2019039673A (ja) * 2017-08-22 2019-03-14 セイコーエプソン株式会社 時間デジタル変換回路、回路装置、物理量測定装置、電子機器及び移動体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
DE69031939T2 (de) 1989-03-28 1998-09-10 Genetics Institute, Inc., Cambridge, Mass. Osteoinduktive zusammensetzungen
WO1991018098A1 (en) 1990-05-16 1991-11-28 Genetics Institute, Inc. Bone and cartilage inductive proteins
JPH0426624A (ja) * 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
JPH05509086A (ja) * 1990-06-22 1993-12-16 イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー イミダゾールアンジオテンシン―２受容体拮抗薬による慢性腎不全の治療
CA2104678C (en) * 1991-03-11 2002-05-14 Charles M. Cohen Protein-induced morphogenesis
US7056882B2 (en) * 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
EP0575555B1 (en) 1991-03-11 2001-07-18 Curis, Inc. Protein-induced morphogenesis
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
CA2116562C (en) 1991-08-30 1999-04-13 Thangavel Kuberasampath Morphogen-induced modulation of inflammatory response
CA2116559C (en) 1991-08-30 2005-05-10 Thangavel Kuberasampath Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
ES2156862T3 (es) 1991-08-30 2001-08-01 Curis Inc Metodo para seleccionar proteinas morfogenicas.
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
EP0661933B1 (en) 1992-07-31 1998-04-22 Creative Biomolecules, Inc. Morphogen-enriched dietary composition
PT653942E (pt) 1992-07-31 2003-11-28 Curis Inc Regeneracao e reparacao de nervos induzidos por morfogenios
AU678380B2 (en) 1992-07-31 1997-05-29 Stryker Corporation Morphogenic protein soluble complex and composition thereof
ES2114073T3 (es) 1992-09-16 1998-05-16 Creative Biomolecules Inc Regeneracion del higado inducida por morfogenes.
EP0672064A1 (en) 1992-11-03 1995-09-20 Creative Biomolecules, Inc. Op-3-induced morphogenesis
US5372335A (en) 1992-12-18 1994-12-13 Scott H. Yenzer Aerial marker ball and method of placement
JPH08510446A (ja) 1993-03-04 1996-11-05 クリエイティブ バイオモレキュルズ，インコーポレイテッド 組換え骨形成タンパク質を生成するための方法および組成物
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
DE69431527T2 (de) * 1993-11-15 2003-06-26 Celtrix Pharma Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US5723411A (en) * 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
ES2201287T5 (es) * 1996-03-22 2007-10-16 Curis, Inc. Metodo para mejorar la recuperacion funcional de la coordinacion motora, del habla o la percepcion sensorial tras una isquemia o trauma del sistema nervioso central.
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Also Published As

Publication number Publication date
ATE245997T1 (de) 2003-08-15
DE69723845D1 (de) 2003-09-04
DE69730966D1 (de) 2004-11-04
US6498142B1 (en) 2002-12-24
EP0914146B1 (en) 2004-09-29
CA2254953A1 (en) 1997-11-13
US20050143304A1 (en) 2005-06-30
US6861404B1 (en) 2005-03-01
US20100291170A1 (en) 2010-11-18
CA2254954C (en) 2010-01-12
DK0910400T3 (da) 2003-11-24
JP5247593B2 (ja) 2013-07-24
EP0914146A1 (en) 1999-05-12
DE69730966T2 (de) 2006-02-23
PT910400E (pt) 2003-12-31
JP2000510835A (ja) 2000-08-22
CA2254953C (en) 2006-09-26
ES2203803T3 (es) 2004-04-16
EP0910400B1 (en) 2003-07-30
WO1997041881A1 (en) 1997-11-13
JP2000510124A (ja) 2000-08-08
EP0910400A1 (en) 1999-04-28
PT914146E (pt) 2005-02-28
ES2230604T3 (es) 2005-05-01
US8377878B2 (en) 2013-02-19
JP2012229268A (ja) 2012-11-22
ATE277629T1 (de) 2004-10-15
CA2254954A1 (en) 1997-11-13
JP2009185076A (ja) 2009-08-20
DE69723845T2 (de) 2004-06-03
AU2832297A (en) 1997-11-26
US7524817B2 (en) 2009-04-28
US20120004171A1 (en) 2012-01-05
US8017580B2 (en) 2011-09-13
JP4766722B2 (ja) 2011-09-07
WO1997041880A1 (en) 1997-11-13
AU2933997A (en) 1997-11-26

Similar Documents

Publication Publication Date Title
DK0914146T3 (da) Morfogenbehandling af kronisk nyresvigt
NO982436D0 (no) Apparat for oppvarming av blod
DE69432582T2 (de) System zur Administration von Flüssigkeiten bei mehreren Patienten
NO970536D0 (no) Behandlingssystem for avgitt blod med skrå reguleringsgrenseflate
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
DE69602624T2 (de) Instrumentation zur Verwendung in der orthopädischen Chirurgie
DK0608313T3 (da) Formuleringer af blodkoagel-polymer-matrix ved afgivelse af osteogene proteiner
FI871288A0 (fi) Menetelmä aprotiniinin valmistamiseksi yhdistelmä-DNA-tekniikalla ja menetelmään soveltuva DNA, ilmentämisplasmidi ja isäntäsolu
DE69726345D1 (de) Apparat zur extrakorporalen Blutbehandlung
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
DK0980252T3 (da) Terapier til akut nyresvigt
DE69636507D1 (de) Blutbehälter, sowie Instrument und Gerät zur Abgabe von Blut
DE69825625D1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
DK0751785T3 (da) Kombinationer af thrombolytisk aktive proteiner og antikoagulationsmidler samt anvendelse heraf
DE69714451T2 (de) Prionbindende proteine und deren verwendungen
ATE329603T1 (de) Implantat mit immunisolierten stromazellen und deren verwendung
DK0809516T3 (da) Medicinsk kombination, som er anvendelig til transfektion og ekspression in vivo af exogener
DK1169058T3 (da) Insulinlignende vækstfaktorbindingsprotein-4-protease
CY1105117T1 (el) Θepαπειες για τη χρονια νεφρικη ανεπαρκεια χρησιμοποιωντας ανταγωνιστες των ενσωματινων
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
DE69623112T2 (de) Einheit zur knorpelreparatur
DK0495226T3 (da) Anvendelse af 3-aryl-5-alkylthio-4H-1,2,4-triazoler til behandling af hyperrefleksi som følge af spinaltrauma
DE69523250D1 (de) Verwendung von Osteoblast-Proliferationsfaktor
ATE204169T1 (de) Polyamin-antagonisten enthaltende intraokulare irrigationslösung